FGP
COGT icon

Freestone Grove Partners’s Cogent Biosciences COGT Stock Holding History

Freestone Grove Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,511
Closed -$98.9K – 703
2025
Q1 		$98.9K Sell
16,511
-15,682
-49% -$123K ﹤0.01% 560
2024
Q4 		$251K Buy
+32,193
New +$321K ﹤0.01% 500

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Freestone Grove Partners's COGT Position: Q2 2025 in Review

Freestone Grove Partners sold out of Cogent Biosciences (COGT) in Q2 2025, closing a stake of 16,511 shares — an estimated $98.9K sold.

Freestone Grove Partners first reported a position in COGT in Q4 2024 and held it in 2 quarters. The position peaked at $251K in Q4 2024. 180 funds tracked by Wall St. Rank hold COGT as of Q2 2025.

  • Freestone Grove Partners reported no remaining Cogent Biosciences position as of Q2 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 16,511 Cogent Biosciences shares in Q2 2025, an estimated $98.9K.
  • Freestone Grove Partners first reported a position in Cogent Biosciences in Q4 2024 and held it in 2 quarters.
  • Freestone Grove Partners's Cogent Biosciences position peaked at $251K in Q4 2024.
  • 180 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2025.

Based on Freestone Grove Partners's 13F filing for Q2 2025, filed 14 Aug 2025.